200 related articles for article (PubMed ID: 34725432)
1. Roles of metal ions in the selective inhibition of oncogenic variants of isocitrate dehydrogenase 1.
Liu S; Abboud MI; John T; Mikhailov V; Hvinden I; Walsby-Tickle J; Liu X; Pettinati I; Cadoux-Hudson T; McCullagh JSO; Schofield CJ
Commun Biol; 2021 Nov; 4(1):1243. PubMed ID: 34725432
[TBL] [Abstract][Full Text] [Related]
2. Differentiating Inhibition Selectivity and Binding Affinity of Isocitrate Dehydrogenase 1 Variant Inhibitors.
Liu S; Abboud M; Mikhailov V; Liu X; Reinbold R; Schofield CJ
J Med Chem; 2023 Apr; 66(7):5279-5288. PubMed ID: 36952395
[TBL] [Abstract][Full Text] [Related]
3. Natural and synthetic 2-oxoglutarate derivatives are substrates for oncogenic variants of human isocitrate dehydrogenase 1 and 2.
Liu X; Reinbold R; Liu S; Herold RA; Rabe P; Duclos S; Yadav RB; Abboud MI; Thieffine S; Armstrong FA; Brewitz L; Schofield CJ
J Biol Chem; 2023 Feb; 299(2):102873. PubMed ID: 36621625
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small molecule.
Deng G; Shen J; Yin M; McManus J; Mathieu M; Gee P; He T; Shi C; Bedel O; McLean LR; Le-Strat F; Zhang Y; Marquette JP; Gao Q; Zhang B; Rak A; Hoffmann D; Rooney E; Vassort A; Englaro W; Li Y; Patel V; Adrian F; Gross S; Wiederschain D; Cheng H; Licht S
J Biol Chem; 2015 Jan; 290(2):762-74. PubMed ID: 25391653
[TBL] [Abstract][Full Text] [Related]
5. Low pH Facilitates Heterodimerization of Mutant Isocitrate Dehydrogenase IDH1-R132H and Promotes Production of 2-Hydroxyglutarate.
Sesanto R; Kuehn JF; Barber DL; White KA
Biochemistry; 2021 Jun; 60(25):1983-1994. PubMed ID: 34143606
[TBL] [Abstract][Full Text] [Related]
6. Biochemical, cellular, and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1.
Davis MI; Gross S; Shen M; Straley KS; Pragani R; Lea WA; Popovici-Muller J; DeLaBarre B; Artin E; Thorne N; Auld DS; Li Z; Dang L; Boxer MB; Simeonov A
J Biol Chem; 2014 May; 289(20):13717-25. PubMed ID: 24668804
[TBL] [Abstract][Full Text] [Related]
7. Computational study on novel natural compound inhibitor targeting IDH1_R132H.
Zhou B; Yang F; Qin L; Kuai J; Yang L; Zhang L; Sun P; Li G; Wang X
Aging (Albany NY); 2022 Jul; 14(13):5478-5492. PubMed ID: 35802554
[TBL] [Abstract][Full Text] [Related]
8. Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer.
Brooks E; Wu X; Hanel A; Nguyen S; Wang J; Zhang JH; Harrison A; Zhang W
J Biomol Screen; 2014 Sep; 19(8):1193-200. PubMed ID: 24980596
[TBL] [Abstract][Full Text] [Related]
9. Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1
Waitkus MS; Pirozzi CJ; Moure CJ; Diplas BH; Hansen LJ; Carpenter AB; Yang R; Wang Z; Ingram BO; Karoly ED; Mohney RP; Spasojevic I; McLendon RE; Friedman HS; He Y; Bigner DD; Yan H
Cancer Res; 2018 Jan; 78(1):36-50. PubMed ID: 29097607
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer.
Wu F; Cheng G; Yao Y; Kogiso M; Jiang H; Li XN; Song Y
Med Chem; 2018; 14(7):715-724. PubMed ID: 29792149
[TBL] [Abstract][Full Text] [Related]
11. Inhibitor potency varies widely among tumor-relevant human isocitrate dehydrogenase 1 mutants.
Avellaneda Matteo D; Wells GA; Luna LA; Grunseth AJ; Zagnitko O; Scott DA; Hoang A; Luthra A; Swairjo MA; Schiffer JM; Sohl CD
Biochem J; 2018 Oct; 475(20):3221-3238. PubMed ID: 30249606
[TBL] [Abstract][Full Text] [Related]
12. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
[TBL] [Abstract][Full Text] [Related]
13. An analysis of the prognostic value of IDH1 (isocitrate dehydrogenase 1) mutation in Polish glioma patients.
Lewandowska MA; Furtak J; Szylberg T; Roszkowski K; Windorbska W; Rytlewska J; Jóźwicki W
Mol Diagn Ther; 2014 Feb; 18(1):45-53. PubMed ID: 23934769
[TBL] [Abstract][Full Text] [Related]
14. Mutant IDH1 promotes phagocytic function of microglia/macrophages in gliomas by downregulating ICAM1.
Ma D; Zhan D; Fu Y; Wei S; Lal B; Wang J; Li Y; Lopez-Bertoni H; Yalcin F; Dzaye O; Eberhart CG; Laterra J; Wilson MA; Ying M; Xia S
Cancer Lett; 2021 Oct; 517():35-45. PubMed ID: 34098063
[TBL] [Abstract][Full Text] [Related]
15. Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis.
Tiburcio PDB; Xiao B; Berg S; Asper S; Lyne S; Zhang Y; Zhu X; Yan H; Huang LE
Acta Neuropathol; 2018 Feb; 135(2):285-298. PubMed ID: 29288440
[TBL] [Abstract][Full Text] [Related]
16. A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas.
Casar-Borota O; Øystese KA; Sundström M; Melchior L; Popovic V
Pituitary; 2016 Aug; 19(4):407-14. PubMed ID: 27097804
[TBL] [Abstract][Full Text] [Related]
17. Molecular mechanisms of "off-on switch" of activities of human IDH1 by tumor-associated mutation R132H.
Yang B; Zhong C; Peng Y; Lai Z; Ding J
Cell Res; 2010 Nov; 20(11):1188-200. PubMed ID: 20975740
[TBL] [Abstract][Full Text] [Related]
18. Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.
Habiba U; Sugino H; Yordanova R; Ise K; Tanei ZI; Ishida Y; Tanikawa S; Terasaka S; Sato KI; Kamoshima Y; Katoh M; Nagane M; Shibahara J; Tsuda M; Tanaka S
Acta Neuropathol Commun; 2021 May; 9(1):95. PubMed ID: 34020723
[TBL] [Abstract][Full Text] [Related]
19. Discovery of a Novel Chemical Scaffold Against Mutant Isocitrate Dehydrogenase 1 (IDH1).
Kang CH; Choi SU; Son YH; Lee HK; Jeong HG; Yun CS; Ahn S; Park CH
Anticancer Res; 2020 Sep; 40(9):4929-4935. PubMed ID: 32878781
[TBL] [Abstract][Full Text] [Related]
20. Monoallelic IDH1 R132H Mutation Mediates Glioma Cell Response to Anticancer Therapies via Induction of Senescence.
Zhan D; Ma D; Wei S; Lal B; Fu Y; Eberhart C; Laterra J; Ying M; Li Y; Meeker A; Lopez-Bertoni H; Xia S
Mol Cancer Res; 2021 Nov; 19(11):1878-1888. PubMed ID: 34348994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
